PEHO syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2836OMIM:260565G31.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

PEHO syndrome (Progressive Encephalopathy with edema, Hypsarrhythmia, and Optic atrophy) is a rare, severe neurodegenerative disorder first described in Finnish families. The acronym captures its cardinal features: progressive encephalopathy (brain dysfunction), subcutaneous edema (particularly of the limbs and face), hypsarrhythmia (a severely abnormal electroencephalographic pattern associated with infantile spasms), and optic atrophy (degeneration of the optic nerves leading to visual impairment or blindness). The condition is caused by biallelic pathogenic variants in the ZNHIT3 gene on chromosome 17q25.1, which encodes a protein involved in small nucleolar ribonucleoprotein (snoRNP) assembly and is essential for normal brain development. Affected infants typically appear normal at birth but develop hypotonia (reduced muscle tone), feeding difficulties, and seizures — often infantile spasms with hypsarrhythmia — within the first weeks to months of life. Progressive cerebellar and cerebral atrophy is evident on brain MRI, and psychomotor development is severely impaired, with most children never achieving independent sitting or purposeful hand use. Dysmorphic features may include a narrow forehead, epicanthal folds, short nose, and open mouth. Peripheral edema of the dorsum of the hands and feet, as well as facial puffiness, is a characteristic finding. Optic atrophy develops during infancy, contributing to severe visual impairment. There is currently no curative treatment for PEHO syndrome. Management is supportive and symptomatic, focusing on seizure control with antiepileptic medications (though seizures are often refractory), nutritional support (frequently requiring gastrostomy tube feeding), physical therapy, and management of respiratory complications. Life expectancy is significantly reduced, though some individuals survive into their teens or beyond with intensive supportive care. The condition is most prevalent in Finland but has been reported worldwide.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal upper lip morphologyHP:0000177
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for PEHO syndrome.

View clinical trials →

No actively recruiting trials found for PEHO syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the PEHO syndrome community →

No specialists are currently listed for PEHO syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to PEHO syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open PEHO syndromeForum →

No community posts yet. Be the first to share your experience with PEHO syndrome.

Start the conversation →

Latest news about PEHO syndrome

No recent news articles for PEHO syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about PEHO syndrome

What is PEHO syndrome?

PEHO syndrome (Progressive Encephalopathy with edema, Hypsarrhythmia, and Optic atrophy) is a rare, severe neurodegenerative disorder first described in Finnish families. The acronym captures its cardinal features: progressive encephalopathy (brain dysfunction), subcutaneous edema (particularly of the limbs and face), hypsarrhythmia (a severely abnormal electroencephalographic pattern associated with infantile spasms), and optic atrophy (degeneration of the optic nerves leading to visual impairment or blindness). The condition is caused by biallelic pathogenic variants in the ZNHIT3 gene on ch

How is PEHO syndrome inherited?

PEHO syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does PEHO syndrome typically begin?

Typical onset of PEHO syndrome is infantile. Age of onset can vary across affected individuals.